Avanos Medical, Inc. Announces Third Quarter 2025 Results

— Delivered double-digit growth in Specialty Nutrition Systems segment — Closed acquisition of Nexus Medical, providing a complementary technology for the Specialty Nutrition Systems segment — Raising and narrowing top-line guidance and adjusted EPS guidance for the full year Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2025 financial results. https://mma.prnewswire.com/media/713850/Avanos_Logo.jpg “I am pleased

Interplay Learning Launches Engagement Services and Expands Apprenticeship Offerings

Interplay Learning, the leader in immersive learning for the skilled trades, today announced the expansion of its Apprenticeship Services and the launch of Engagement Services. These strategic services are designed to help organizations tackle two of the industry's biggest challenges: developing qualified workers and keeping learners engaged in ongoing training and professional development. https://mma.prnewswire.com/media/2812436/Interplay_Learning_Logo.jpg With

OPENLANE, Inc. Reports Third Quarter 2025 Financial Results

— Marketplace dealer volume growth of 14% YoY — Gross Merchandise Value (GMV) of approximately $7.3 billion, representing 9% YoY growth — Revenue of $498 million, representing 8% YoY growth, driven by 20% growth in auction fee revenue — Income from continuing operations of $48 million, representing 69% YoY growth — Adjusted EBITDA of $87

Secura Bio to Participate in the Jefferies Global Healthcare Conference in London

Secura Bio to Participate in the Jefferies Global Healthcare Conference in London GlobeNewswire November 05, 2025 BERKELEY HEIGHTS, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) — Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that Chip Romp, Chief Executive Officer, and Will Brown, Chief Financial Officer will participate

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire November 05, 2025 RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired employees restricted stock units (RSUs) covering an aggregate of 30,700 shares of BioCryst

Astec Reports Third Quarter 2025 Results

Astec Reports Third Quarter 2025 Results GlobeNewswire November 05, 2025 Third Quarter 2025 Overview (all comparisons are made to the corresponding prior year third quarter unless otherwise specified): Net sales of $350.1 million Net loss of $4.2 million; Adjusted net income of $10.8 million EBITDA of $13.8 million; Adjusted EBITDA of $27.1 million Diluted EPS

McDONALD’S REPORTS THIRD QUARTER 2025 RESULTS

— Global comparable sales increased 3.6%, with broad-based growth across all segments — Global Systemwide sales* were over $36 billion for the quarter, an increase over prior year of 8% (6% in constant currency) — Systemwide sales to loyalty members across 60 loyalty markets were approximately $34 billion for the trailing twelve-month period and over

Enbridge Inc. Declares Quarterly Dividends

Enbridge Inc. (TSX: ENB) (NYSE: ENB) (Enbridge or the Company) announced that its Board of Directors has declared a quarterly dividend of $0.9425 per common share, payable on December 1, 2025 to shareholders of record on November 14, 2025. The amount of the dividend is consistent with the September 1, 2025 dividend. The Board also

Immunoassays Market Size to Hit USD 42.77 Billion by 2034

Ottawa, Nov. 05, 2025 (GLOBE NEWSWIRE) — The global Immunoassays Market size is calculated at USD 27.25 billion in 2024, grew to USD 28.51 billion in 2025, and is projected to reach around USD 42.77 billion by 2034. The market is projected to expand at a CAGR of 4.62% between 2025 and 2034. Immunoassays Market

Scroll to Top